The predominance of downregulating TCR-ζ in SF CD8+CD28null cells in patients with seronegative arthritides suggests that TCR molecules in CD8+CD28− cells may serve as a biomarker in RA [60]. This evidence concerns the gene CD8A and rheumatoid arthritis.